Stanford Medicine researchers have developed an artificial intelligence tool to help scientists better plan gene-editing ...

CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds ...

(MENAFN- GlobeNewsWire - Nasdaq) CRISPR-based therapeutics present market opportunities in infectious diseases through genome disruption, host gene editing, and immune cell engineering. Key areas ...

When the genome-editing tool CRISPR is thought of as a potential medicine, the targets that first come to mind are diseases like sickle cell or other conditions caused by particular mutations. Use ...

Banas is associate director of research at the Gene Editing Institute at ChristianaCare, where Kmiec is founder and executive director. The medical promise of CRISPR gene editing can be seen most ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

The United Nations predicts that there will be an additional 2.2 billion people on the planet by 2050. To help feed the growing population, the food industry must overcome several critical challenges, ...

This includes the labeling of the dCas9 protein, engineering of sgRNA, and the use of dCas9 orthologs from different bacterial species. CRISPR, clustered regularly interspaced short palindromic ...

Dublin, Aug. 29, 2025 (GLOBE NEWSWIRE) -- The "CRISPR Gene Editing in Infectious Diseases: Market Overview" report has been added to ResearchAndMarkets.com's offering. The report provides an overview ...